ArticleOpen medicine (Warsaw, Poland)2026
Long-term regulatory effects of high-fiber low-fat diet on gut microbiota diversity and inflammatory marker expression in DSS-induced recurrent colitis in mice.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the long-term regulatory effects of high-fiber low-fat (HFLF) diet on gut microbiota diversity and inflammation/barrier-related markers in DSS-induced recurrent colitis mice. Methods: A recurrent DSS model was established through multiple cycles of DSS administration. Mice were randomly assigned to HFLF diet vs. control/standard chow ± positive control groups. Multi-timepoint sampling was conducted throughout the study. 16S rRNA sequencing, SCFA quantification, and qPCR/ELISA/immunohistochemistry/Western blot analyses were performed. Results: HFLF diet significantly improved clinical phenotype, increased gut microbiota diversity, promoted beneficial bacterial genera, enhanced SCFA production, and modulated inflammation/barrier indicators throughout the recurrence-remission cycles. Conclusions: HFLF diet provides sustained protection during recurrence-remission processes through microbiota-SCFA-inflammation axis modulation, offering potential translational applications for IBD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.